Guardant Health, Inc. (NASDAQ: GH) saw its shares surge over 28% on Thursday, hitting a three-year high after the precision oncology company reported third-quarter earnings that handily beat expectations and raised its full-year revenue guidance.
The robust quarterly performance propelled the stock to break decisively out of a cup-shaped base pattern, clearing a key buy point of $68. The rally extends the stock’s year-to-date gain to over 100%, reflecting strong investor confidence in the company’s growth trajectory.
Guardant Health’s Q3 revenue jumped 39% year-over-year to $265.2 million, demonstrating broad-based strength across its business segments.
The strong top-line growth also led to an improved bottom line. The company’s adjusted net loss narrowed to $48.3 million, compared to a loss of $55.0 million in the same period last year.
Bolstered by these results, management raised its full-year 2025 revenue outlook. The company now anticipates revenue in the range of $965 million to $970 million, representing growth of approximately 31% at the midpoint.
A key highlight for analysts was the accelerating sequential growth in clinical test volumes. Andrew Brackmann, an analyst at William Blair, noted in a report that volume growth accelerated from 25% in Q1 to 30% in Q2, and further to 40% in Q3. He expects this positive trajectory “not to slow meaningfully.”
Brackmann attributes this momentum to the expanding use of the Guardant360 liquid biopsy test, an upgraded tissue-based testing product, and progress in securing Medicare reimbursement for the Reveal test.
Guardant Health’s competitive edge lies in its innovative liquid biopsy technology. The Guardant360 test utilizes advanced genomic sequencing to help physicians identify appropriate therapies for patients with solid tumors such as lung, breast, colon, and prostate cancer. Meanwhile, the Shield test offers a more convenient alternative to colonoscopy and stool-based tests for colorectal cancer screening.
